AbbVie Executive Says Company Cut 2024 U.S. Humira Sales Forecast By $400M To $7.4B To Reflect More Shift In Volume, Including To Skyrizi And Rinvoq
Portfolio Pulse from Benzinga Newsdesk
AbbVie has reduced its 2024 U.S. sales forecast for Humira by $400 million to $7.4 billion, reflecting a shift in volume to other products like Skyrizi and Rinvoq.
October 30, 2024 | 1:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AbbVie has lowered its 2024 U.S. sales forecast for Humira by $400 million, now expecting $7.4 billion. This adjustment reflects a shift in volume to Skyrizi and Rinvoq.
The reduction in Humira's sales forecast suggests a potential decline in revenue from this product, which could negatively impact AbbVie's short-term stock price. However, the shift to Skyrizi and Rinvoq may offset some of this impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100